iPhone | iPad
Android
Huawei
The country’s GPW will primarily be supported by ongoing infrastructure spending and an expected increase in visitors and residents
KT APPDOWNLOAD
Healthcare giant Johnson & Johnson to split into two companies
The move is in line with other multinational companies adopting the strategy to simplify their structure.
Reuters file
Healthcare conglomerate Johnson & Johnson said on Friday it is planning to break up into two companies, splitting off its consumer health division that sells Band-Aids and Baby Powder from its large pharmaceuticals unit.
The move is in line with other multinational companies adopting the strategy to simplify their structure. Earlier in the day, Toshiba Corp announced similar plans, while General Electric Co said on Wednesday it would break up into three to pare down its debt.
Johnson & Johnson said it will separate its consumer health business into a new publicly traded company.
Other drugmakers have in the past separated their consumer health businesses from their pharmaceutical units.
Rival Pfizer Inc had in 2019 combined its consumer health unit with GlaxoSmithKline plc in a joint venture, while Germany's Merck KGaA sold its consumer health unit to Procter & Gamble Co in 2018.
"The new Johnson & Johnson and the New Consumer Health Company would each be able to more effectively allocate resources to deliver for patients and consumers, drive growth and unlock significant value," said Joaquin Duato, who is expected to become J&J's chief executive officer in January.
The company is aiming to complete the planned separation in 18 to 24 months, sending its shares up 4 per cent before the bell.
Johnson & Johnson retain its pharmaceuticals and medical device units, which sells its Covid-19 vaccine and drugs such as cancer treatment Darzalex. The units are expected to generate revenue of roughly $77 billion in 2021.
More news from Business
New strategy will promote the economic and social development of the Emirate of Sharjah
The ADX-listed company said it secured all regulatory approvals and reduced its share capital to Dh1.435 billion from Dh2.325 billion to absorb all the accumulated losses
The UAE government is expected to announce its corporate tax policy framework, including its transfer pricing regulation, this summer
Excellent half year results and successful strategic execution are testament to the vital role that the company is playing in enabling significant production capacity growth for Adnoc as well as the UAE’s objective to achieve gas self-sufficiency
Yahsat is on track to grow 2022 financial year dividend by at least two per cent to 16.12 fils per share or Dh393 million ($107 million), split into two equal instalments payable around October 2022 and May 2023
The transaction is subject to customary closing conditions, including receipt of Canadian regulatory approvals, and is expected to close in the next 60 days
Strong result driven primarily by subsidiary's solid performance and profitable business acquisitions in first half 2022; H1 total revenue climbs 121% to Dh21.93 billion